| EverlastingButterfly.com |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
EB LINKS
|
OTHER LINKS TO LEARN MORE ABOUT EB
EB MEDICAL RECORDS/JOURNALS
You can click on the links below for medical records for the particular EB Subtype your are looking for.
|
New funding scheme will make E6m available for health research
Irish Medical News - Dublin,Ireland
Research teams investigating common and rare diseases such as cancer, retinitis
pigmentosa (a form of blindness), epidermolysis bullosa (a rare skin ...
Irish Medical News - Dublin,Ireland
Research teams investigating common and rare diseases such as cancer, retinitis
pigmentosa (a form of blindness), epidermolysis bullosa (a rare skin ...
FDA Issues Approvable Letter to Ortec for Use of Cryopreserved OrCel(R) in Epidermolysis
Bullosa Patients' Hand Ortec International, Inc. , a company focused on advancing
regenerative medicine through the development of cellular technology and advanced
biomaterial products, has been notified by the Food and Drug Administration that its HDE
Supplement is approvable subject to an inspection by the FDA of its commercial
manufacturing facility. Posted 09-30-06
Bullosa Patients' Hand Ortec International, Inc. , a company focused on advancing
regenerative medicine through the development of cellular technology and advanced
biomaterial products, has been notified by the Food and Drug Administration that its HDE
Supplement is approvable subject to an inspection by the FDA of its commercial
manufacturing facility. Posted 09-30-06
Ortec Obtains Second US Patent Allowance on Haptide Cell ...
PharmaLive.com (press release) - Newtown,PA,USA
... Ortec has already obtained FDA approvals for use of a nonfrozen version of OrCel® in
the treatment of Epidermolysis Bullosa and donor sites in burn patients. ...Posted 09-21-06
PharmaLive.com (press release) - Newtown,PA,USA
... Ortec has already obtained FDA approvals for use of a nonfrozen version of OrCel® in
the treatment of Epidermolysis Bullosa and donor sites in burn patients. ...Posted 09-21-06
RegeneRx Receives $545,000 Grant from FDA; Funding for Clinical ... Genetic Engineering
News (press release) - Larchmont,NY,USA ... The two-year grant will be utilized for
RegeneRx's Phase II Epidermolysis Bullosa (EB) clinical trial, which is currently enrolling
patients. ... Posted 08-17-06
News (press release) - Larchmont,NY,USA ... The two-year grant will be utilized for
RegeneRx's Phase II Epidermolysis Bullosa (EB) clinical trial, which is currently enrolling
patients. ... Posted 08-17-06
Plectin-controlled keratin cytoarchitecture affects MAP kinases ... Journal of Cell Biology
(subscription) - USA ... Abbreviations used in this paper: EBS, epidermolysis bullosa simplex;
HD, hemidesmosome; IF, intermediate filament; OA, okadaic acid; RACK, receptor for ...
Posted 08-17-06
(subscription) - USA ... Abbreviations used in this paper: EBS, epidermolysis bullosa simplex;
HD, hemidesmosome; IF, intermediate filament; OA, okadaic acid; RACK, receptor for ...
Posted 08-17-06
Ortec seeks OK of OrCel for skin disorder United Press International - USA NEW YORK, May 30
(UPI) -- Ortec said Tuesday it has filed for a "humanitarian device" exemption to get OrCel
cleared to treat epidermolysis bullosa. ... See all stories on this topic Posted 06-01-06
(UPI) -- Ortec said Tuesday it has filed for a "humanitarian device" exemption to get OrCel
cleared to treat epidermolysis bullosa. ... See all stories on this topic Posted 06-01-06
Ortec Announces Formation of Stem Cell and Regenerative Medicine ... PR Newswire (press
release) - New York,NY,USA ... Ortec has already obtained FDA approvals for use of a
non-frozen version of OrCel(R) in the treatment of Epidermolysis Bullosa and donor sites in
burn patients ... Posted 04-26-06
release) - New York,NY,USA ... Ortec has already obtained FDA approvals for use of a
non-frozen version of OrCel(R) in the treatment of Epidermolysis Bullosa and donor sites in
burn patients ... Posted 04-26-06
PTC Therapeutics Initiates Phase 2 Study of PTC124 in Duchenne ... PR Newswire
(press release) - New York,NY,USA ... In addition to CF and DMD, other potential
indications include hemophilia, neurofibromatosis, retinitis pigmentosa, epidermolysis
bullosa, and lysosomal ... Posted 02-01-06
(press release) - New York,NY,USA ... In addition to CF and DMD, other potential
indications include hemophilia, neurofibromatosis, retinitis pigmentosa, epidermolysis
bullosa, and lysosomal ... Posted 02-01-06
Ortec expands focus to stem cell and regenerative medicine with ... American Venture
Magazine (press release) - Palo Alto,CA,USA ... In addition to having received FDA
approvals for the treatment of Epidermolysis Bullosa and donor sites in burn patients, a
pivotal clinical trial has been ... Posted 1-3-06
Magazine (press release) - Palo Alto,CA,USA ... In addition to having received FDA
approvals for the treatment of Epidermolysis Bullosa and donor sites in burn patients, a
pivotal clinical trial has been ... Posted 1-3-06
New Gene Therapy Method to help Muscular Dystrophy -- Muscle ... Best Syndication -
Pinon Hills,CA,USA ... but Calos is self-assured that her method looks promising and
hope it will lead to the cure of hemophilia, skin disease, epidermolysis bullosa as well
as ... Posted 12/30/05
Pinon Hills,CA,USA ... but Calos is self-assured that her method looks promising and
hope it will lead to the cure of hemophilia, skin disease, epidermolysis bullosa as well
as ... Posted 12/30/05
Gene therapy for muscular dystrophy fixes frail muscle cells in ... EurekAlert (press
release) - Washington,DC,USA ... technique will be a part of the journey towards a cure
for the disease and for other diseases such as hemophilia and the skin disease,
epidermolysis bullosa. ... Posted 12/30/05
release) - Washington,DC,USA ... technique will be a part of the journey towards a cure
for the disease and for other diseases such as hemophilia and the skin disease,
epidermolysis bullosa. ... Posted 12/30/05
PTC Therapeutics Initiates Second Phase 2 Study of PTC124 in ... Yahoo! News (press
release) - USA ... In addition to CF and DMD, other potential indications include
hemophilia, neurofibromatosis, retinitis pigmentosa, epidermolysis bullosa, and
lysosomal Posted 12/30/05
release) - USA ... In addition to CF and DMD, other potential indications include
hemophilia, neurofibromatosis, retinitis pigmentosa, epidermolysis bullosa, and
lysosomal Posted 12/30/05
Ortec Expands Focus to Stem Cell and Regenerative Medicine with ... PR Newswire (press
release) - New York,NY,USA ... In addition to having received FDA approvals for the
treatment of Epidermolysis Bullosa and donor sites in burn patients, a pivotal clinical
trial has been ... Posted 12-16-05
release) - New York,NY,USA ... In addition to having received FDA approvals for the
treatment of Epidermolysis Bullosa and donor sites in burn patients, a pivotal clinical
trial has been ... Posted 12-16-05
FDA's Office of Orphan Products Development Awards PTC Therapeutics a Grant to
Support Clinical Development of PTC124 for the Treatment of
Nonsense-Mutation-Mediated Cystic Fibrosis Posted 12-07-05
Support Clinical Development of PTC124 for the Treatment of
Nonsense-Mutation-Mediated Cystic Fibrosis Posted 12-07-05
| EverlastingButterfly.com is here to help answer any questions that we can. We do not claim to be experts, but will do the necessary research to help answer questions that you may have. So please feel free to email us at: eb@everlastingbutterfly.com. |
DISCLAIMER
www.EverlastingButterfly.com does not validate information gathered
from links of EB Websites, Personal Pages, etc. We are simply just trying
to spread awareness of Epidermolysis Bullosa. We are not medically
qualified in EB, but are simply offering information that can be discussed
with your doctor with the hopes that it improves the care and quality of
life for EB patients and parents. The above information was attained
from the Debra website for a general description of EB. You will find much
more detailed information at www.debra.org.
www.EverlastingButterfly.com does not validate information gathered
from links of EB Websites, Personal Pages, etc. We are simply just trying
to spread awareness of Epidermolysis Bullosa. We are not medically
qualified in EB, but are simply offering information that can be discussed
with your doctor with the hopes that it improves the care and quality of
life for EB patients and parents. The above information was attained
from the Debra website for a general description of EB. You will find much
more detailed information at www.debra.org.
| www.EverlastingButterfly.com |
| EBINFO.HOMESTEAD.com |
Information gathered from www.debra.org
Epidermolysis bullosa (EB) is a rare genetic disease characterized by the presence of extremely fragile
skin and recurrent blister formation, resulting from minor mechanical friction or trauma. This condition is
not contagious.
An estimated 2 out of every 100,000 live births are affected with some type of EB. The disorder occurs in
every racial and ethnic group throughout the world and affects both sexes equally.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Most forms of EB are inherited although it may also rarely arise as an acquired, autoimmune, bullous
disease known as EB Aquisita. Our focus is on the inherited forms of EB, each of which range from mild to
severe and can require major adjustments in the lifestyle of both the EB patient and his or her family.
There are three main forms of inherited EB: EB Simplex, Junctional EB and Dystrophic EB. These
different subtypes are defined by the depth of blister location within the skin layers.
Blister formation of EB simplex is within the epidermis. Sometimes EB simplex is called epidermolytic.
Blister formation in Junctional EB is seen at the level of the lamina lucida within the basement membrane
zone. Dystrophic EB or dermolytic EB is a scarring form of EB which occurs in the deeper tissue at the level
the lamina densa or upper dermis.
In severe EB, blisters are not confined to the outer skin. They may develop on the soft tissues (mucous
membranes) inside the body such as the linings of the mouth, esophagus, stomach, intestines, lungs,
bladder and genitals. The extent of tissue involvement experienced by an individual is usually determined
by the severity of the disease and the subtype present.
Learn more about EB @ www.debra.org such as:
Testing for EB
How is Epidermolysis Bullosa Inherited?
How is EB Treated?
Support Groups
You may contact DebRA of America with questions or concerns:
Madeline Weiner, RN
EB Nurse Educator
866-332-7276
debra.nurse@mindspring.com
www.debra.org
--------------------------------------------------------------------------------
*Please note that all medical information given by DebRA is for informational purposes only. Our
information is not intended to substitute the care and guidance given by a qualified physician. All
regimens of care should be discussed with the patient's physician. Always check with your physician prior to
starting any medications or treatment regimens.
Epidermolysis bullosa (EB) is a rare genetic disease characterized by the presence of extremely fragile
skin and recurrent blister formation, resulting from minor mechanical friction or trauma. This condition is
not contagious.
An estimated 2 out of every 100,000 live births are affected with some type of EB. The disorder occurs in
every racial and ethnic group throughout the world and affects both sexes equally.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Most forms of EB are inherited although it may also rarely arise as an acquired, autoimmune, bullous
disease known as EB Aquisita. Our focus is on the inherited forms of EB, each of which range from mild to
severe and can require major adjustments in the lifestyle of both the EB patient and his or her family.
There are three main forms of inherited EB: EB Simplex, Junctional EB and Dystrophic EB. These
different subtypes are defined by the depth of blister location within the skin layers.
Blister formation of EB simplex is within the epidermis. Sometimes EB simplex is called epidermolytic.
Blister formation in Junctional EB is seen at the level of the lamina lucida within the basement membrane
zone. Dystrophic EB or dermolytic EB is a scarring form of EB which occurs in the deeper tissue at the level
the lamina densa or upper dermis.
In severe EB, blisters are not confined to the outer skin. They may develop on the soft tissues (mucous
membranes) inside the body such as the linings of the mouth, esophagus, stomach, intestines, lungs,
bladder and genitals. The extent of tissue involvement experienced by an individual is usually determined
by the severity of the disease and the subtype present.
Learn more about EB @ www.debra.org such as:
Testing for EB
How is Epidermolysis Bullosa Inherited?
How is EB Treated?
Support Groups
You may contact DebRA of America with questions or concerns:
Madeline Weiner, RN
EB Nurse Educator
866-332-7276
debra.nurse@mindspring.com
www.debra.org
--------------------------------------------------------------------------------
*Please note that all medical information given by DebRA is for informational purposes only. Our
information is not intended to substitute the care and guidance given by a qualified physician. All
regimens of care should be discussed with the patient's physician. Always check with your physician prior to
starting any medications or treatment regimens.
EPIDERMOLYSIS BULLOSA
EB SUBTYPES
www.EverlastingButterfly.com
EB@ .com
One Genetic Mutation Heals Another In Blistering Skin Disease
Science Daily (press release) - USA
Science Daily — Mutations in the laminin beta 3 (LAMB3) gene cause the blistering skin
disease epidermolysis bullosa (EB). In the May 1st issue of the ...
Science Daily (press release) - USA
Science Daily — Mutations in the laminin beta 3 (LAMB3) gene cause the blistering skin
disease epidermolysis bullosa (EB). In the May 1st issue of the ...
Scientists identify protein that plays key role in skin cancer
Hindustan Times - New Delhi,Delhi,India
Researchers studied 12 children suffering from recessive dystrophic epidermolysis bullosa,
a rare skin disorder. Two-thirds of children with the condition ...
Hindustan Times - New Delhi,Delhi,India
Researchers studied 12 children suffering from recessive dystrophic epidermolysis bullosa,
a rare skin disorder. Two-thirds of children with the condition ...
The Cartilage Matrix Protein Subdomain of Type VII Collagen Is ...
Am J Pathology (subscription) - USA
Epidermolysis bullosa acquisita (EBA) is an acquired bullous disease of the skin
characterized by IgG autoantibodies against type VII (anchoring fibril) ...
Am J Pathology (subscription) - USA
Epidermolysis bullosa acquisita (EBA) is an acquired bullous disease of the skin
characterized by IgG autoantibodies against type VII (anchoring fibril) ...
A Monsta Midget Design
RegeneRx Receives US Patent for Wound Healing Technology
Business Wire (press release) - San Francisco,CA,USA
... epidermolysis bullosa, a difficult-to-heal skin blistering disease and orphan indication;
and diabetic patients undergoing corneal surgery. ...
Business Wire (press release) - San Francisco,CA,USA
... epidermolysis bullosa, a difficult-to-heal skin blistering disease and orphan indication;
and diabetic patients undergoing corneal surgery. ...
Stem cells to treat damaged eyes and a rare skin disorder
News-Medical.net - Sydney,Australia
The researchers then turned their attention to a rare but debilitating genetic disease of the
skin resulting in a syndrome known as Epidermolysis Bullosa, ...
News-Medical.net - Sydney,Australia
The researchers then turned their attention to a rare but debilitating genetic disease of the
skin resulting in a syndrome known as Epidermolysis Bullosa, ...
Forticell Bioscience Announces Collaboration Agreement with CJ ...
Trading Markets (press release) - Los Angeles,CA,USA
Forticell has already obtained FDA approvals for use of a non-frozen version of OrCel(R)
in the treatment of Epidermolysis Bullosa and donor sites in burn ...
Trading Markets (press release) - Los Angeles,CA,USA
Forticell has already obtained FDA approvals for use of a non-frozen version of OrCel(R)
in the treatment of Epidermolysis Bullosa and donor sites in burn ...
| STANFORD SCHOOL OF MEDICINE Epidermolysis Bullosa Clinic Care Videos and Guides |
